One year in review 2020: novelties in the treatment of rheumatoid arthritis.

One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):181-194 Authors: Silvagni E, Giollo A, Sakellariou G, Ughi N, D'Amico ME, Scirè CA, Huizinga TWJ Abstract Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients’ preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions. PMID: 32213264 [PubMed - in process]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Related Links:

Authors: Shi YQ, Qi WF, Kong CY Abstract Rheumatoid arthritis (RA), which normally manifests as a multi‑joint inflammatory reaction, is a common immunological disease in clinical practice. However, the pathogenesis of RA has not yet been fully elucidated. Rituximab (RTX) is an effective drug in the treatment of RA, however its therapeutic efficacy and mechanism of action require further investigation. Thus, the present study aimed to screen the candidate key regulatory genes and explain the potential mechanisms of RA. Gene chips of RA and normal joint tissues were analyzed and, gene chips of RTX before and after ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Sekiguchi Y, Iizuka H, Takizawa H, Sugimoto K, Sakajiri S, Inano T, Fukuda Y, Shirane S, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Sekiguchi N, Noguchi M Abstract A 53-year-old woman had been diagnosed with rheumatoid arthritis (RA) in X-6. She was started on methotrexate (MTX) in X-1. She developed a cough, and chest computed tomography showed abnormalities. In X, MTX was discontinued, but the cough persisted. A lung biopsy revealed a diagnosis of nodular sclerosis classic Hodgkin lymphoma (CHL-NS). She was considered to have "other iatrogenic immunodeficiency-associated lymphoproli...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Publication date: Available online 28 May 2020Source: The Egyptian RheumatologistAuthor(s): Rasha M. Fawzy, Gamal A. Hammad, Samy E. Egila, Amira N. Elkasas, Nehad A. Fouad
Source: The Egyptian Rheumatologist - Category: Rheumatology Source Type: research
ConclusionsAcetabular cups in primary cementless THAs of RA patients were less stable in terms of cup migration compared with that of OA patients.
Source: International Orthopaedics - Category: Orthopaedics Source Type: research
Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al. Clin Exp Rheumatol. 2020 May-Jun;38(3):585 Authors: Pablos JL, Navarro F, Blanco FJ, Román-Ivorra JA, Alonso A, Martín Mola E, Cantalejo M, Ercole L, Rivero N PMID: 32456768 [PubMed]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Conditions:   COVID-19;   Rheumatoid Arthritis Intervention:   Other: Serological analyses to be lead on a pre-existing biobank Sponsor:   University Hospital, Montpellier Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Drug Updates Biologics melanoma skin skin cancer Source Type: research
Conditions:   COVID-19;   Rheumatoid Arthritis Intervention:   Other: Serological analyses to be lead on a pre-existing biobank Sponsor:   University Hospital, Montpellier Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Tarn JR, Lendrem DW, Isaacs JD Abstract INTRODUCTION: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease. Early referral and treatment are key to the effective management of the disease. This makes imperative the identification of biomarkers and of pathobiological endotypes. AREAS COVERED: This review describes recent efforts to integrate large-scale datasets for the identification of disease endotypes for precision medicine in early, seropositive RA. We conducted a search for systems and multi-omics papers in early RA patients through to 1 January 2020. We reviewed investigations of m...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Purpose of review This review encompasses a detailed history of spondyloarthritis (SpA) evolution as early as the 17th century, continues on to the current concept of SpA, and ends with current gaps in our understandings of SpA. Recent findings Until the early 1960s, ankylosing spondylitis and other SpA family members were considered to be variants of rheumatoid arthritis (RA). The formal medical community separated them from RA at that time, and shortly thereafter they were recognized to be inter-connected based on shared clinical, laboratory, and imaging features. The last two decades have witnessed the formal disti...
Source: Current Opinion in Rheumatology - Category: Rheumatology Tags: SPONDYLOARTHROPATHIES: Edited by Joerg Ermann Source Type: research
More News: Arthritis | Rheumatoid Arthritis | Rheumatology